Non-small cell lung cancer
RecruitingA study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer
A study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer
- Disease:Non-small cell lung cancer
- Substances:InfliximabRamucirumab+3
Italy- Participants:18–64 years · 65+ years
- Substances:Infliximab
- Sponsor:AstraZeneca AB















